Discovery may help provide clues for fighting and treating HPV
Yale Cancer Center (YCC) scientists have filled in a key gap in understanding the unusual route by which the Human papillomavirus (HPV) infects cells. Their findings, published online today in the journal Cell, may eventually help to broaden the scope of defenses against HPV and provide valuable clues for delivering drugs into cells. HPV is a family of killers. Although there are effective vaccines against these viruses, they still cause about 5% of cancer deaths worldwide, including more than 250,000 women who die of cervical cancer each year.
Program Project Grant Renewed
The National Cancer Institute recently awarded a five-year, $4.7 million program project grant to investigators at Yale School of Medicine to continue studies on the role of viruses in tumorigenic transformation of cells. Virus infection is thought to account for approximately 15% of all human cancers worldwide, and studies of tumor viruses have historically provided insight into basic cellular processes including carcinogenesis, cell cycle control, and signal transduction.
New Simple Proteins Play Active Role in Cellular Function
Yale scientists have developed simple new proteins almost devoid of chemical diversity that still play a surprisingly active and specific role in cellular function, causing cells to act like cancer cells, they report Aug. 10 in the Proceedings of the National Academy of Sciences.
$7.5 Million Grant to Yale Researchers for Role of Viruses in Cancer
The National Cancer Institute recently awarded a five-year, $7.5 million program project grant to investigators at the Yale School of Medicine to continue studies on the role of viruses and mutant cellular proteins in tumorigenic transformation of cells.
Panel to Examine the Ongoing Evolution of Antibody Drug Conjugates in the Treatment of Breast Cancer
Antibody drug conjugates (ADCs), which use a targeted monoclonal antibody to deliver a cytotoxic payload, are among the most effective breast cancer therapies yet developed. The first Food and Drug Administration approval of an ADC in breast cancer, ado-trastuzumab emtansine, better known as T-DM1, sparked development of numerous new and promising ADCs for breast cancer.Source: SABCS Meeting News
Kirstie Alley and Colon Cancer: The Early Signs You Shouldn't Ignore
Actor Kirstie Alley has died after being diagnosed with colon cancer earlier this year. Colon cancer, also known as colorectal cancer, is the third most common type of cancer in the United States and globally. In the U.S. over 151,000 people will develop the disease in 2022.Source: Healthline
Spatial and Single Cell Characterization of Breast Cancer Progression: Presenter Profile
Presentation is about methods for assessment of multiple molecular variables on a single piece of tissue to better understand breast cancer (or really any cancer) with respect to progression or response or resistance to specific therapies.Source: SABCS Meeting News
Trastuzumab Deruxtecan Generates OS Benefit Vs Capecitabine-based Regimens in Pretreated HER2+ Breast Cancer
Trastuzumab deruxtecan demonstrated a 34% reduction in the risk of death and a 13-month increase in overall survival compared with treatment of physician’s choice in patients with advanced HER2-positive unresectable and/or metastatic breast cancer who received prior treatment with trastuzumab emtansine.Source: OncLive
Berzosertib Plus Standard Chemoradiation Elicits Promising Responses in Locally Advanced HNSCC
Aarti Bhatia, MD, discusses the rationale for investigating berzosertib in this patient population, key updates from the phase 1 trial, and how these findings support the need for continued research of novel regimens in HNSCC.Source: OncLive
Career Path: Women in Leadership at High Levels
Reaching high-level leadership positions in medicine—and specifically oncology—is not an easy task and requires significant time and dedication. For women, there are a host of additional challenges to contend with as they navigate their career.Source: Oncology Times
Role of Nutrient May Reveal Dietary Target in Fight Against Microbial Infections
A nutrient that is common in the human diet has been found to aid the survival of a cancer-causing bacterium, a new Yale study finds. The findings could reveal an important target for new drugs to tackle numerous infectious diseases in humans.Source: Yale West Campus
Smilow Cancer Hospital and Yale Police Team to Raise Breast Cancer Awareness
Members of Smilow Cancer Hospital and Yale Cancer Center spent time together on Friday, October 28 on the New Haven Green with members of the Yale Police Department – along with a special, pink-themed Yale Police SUV – to highlight Breast Cancer Awareness Month.
New Findings on Endometrial Cancer Treated With Pembrolizumab
New research from Yale Cancer Center reveals for the first time ever a differential clinical response to pembrolizumab in Lynch-like (mutated) vs methylated microsatellite instability-high (MSI-H) uterine cancer patients, increasing our understanding about the proportion of patients that derive benefit from immune checkpoint blockade.
Scientists researching new scientific approach to identify cancer origins
Previous studies have shown the connection between age, exposure to carcinogens and the risk of developing cancer due to the accumulation of mutations over time. Scientists from Yale University and Emmanuel College demonstrate a new scientific approach to determine the origins of different types of cancer. Jeffrey Townsend, YSPH Elihu Professor of Biostatistics and Ecology & Evolutionary Biology, was a co-author of the study.Source: The Daily Campus
Dhanpat Jain, MD, Joins Pathologists Nationwide in Calling for Continued Use of Remote Work in Clinical Laboratories and Pathology
A group of pathologists and laboratory leaders from across the U.S. is urging federal officials to continue certain regulatory exemptions implemented during the COVID-19 pandemic that allow the use of remote work in clinical laboratories and pathology.